The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Personalized dendritic cell vaccine for acute leukemia and multiple myeloma
In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of personalized vaccines, which aim to produce tumor-specific immunity. Prof. Avigan discusses the settings that this has proven most successful in, and highlights promising pre-clinical and clinical trials. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.
